Global Economic Slowdown/Uncertainty, potentially leading to reduced investor confidence in speculative growth stocks like biotech.

Elevated Interest Rate Environment, as a strong US economy might keep interest rates higher, increasing the cost of capital for R&D-intensive biotech companies.

Regulatory and Clinical Trial Outcomes in Biotechnology, which are always critical for the success and valuation of gene-editing companies like Beam Therapeutics.